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The concentration of nucleosomes is elevated in blood
of patients with diseases which are associated with
enhanced cell death. In order to detect these circulat-
ing nucleosomes, we used the Cell Death Detection-
ELISAplus (CDDE) from Roche Diagnostics (Mannheim,
Germany) (details at http:\\biochem.roche.com). For
its application in liquid materials we performed vari-
ous modifications: we introduced a standard curve
with nucleosome-rich material, which enabled direct
quantification and improved comparability of the val-
ues within (CVintraassay:3.0–4.1%) and between several
runs (CVinterassay:8.6–13.5%), and tested the analytical
specificity of the ELISA.
Because of the fast elimination of nucleosomes from
circulation and their limited stability, we compared
plasma and serum matrix and investigated in detail
the pre-analytical handling of serum samples which
can considerably influence the test results. Careless
venipuncture producing hemolysis, delayed centrifu-
gation and bacterial contamination of the blood sam-
ples led to false-positive results; delayed stabilization
with EDTA and insufficient storage conditions resulted
in false-negative values. At temperatures of –20 °C,
serum samples which were treated with 10 mM EDTA
were stable for at least 6 months. In order to avoid pos-
sible interfering factors, we recommend a schedule for
the pre-analytical handling of the samples.
As the first stage, the possible clinical application
was investigated in the sera of 310 persons. Patients
with solid tumors (n=220; mean=361 Arbitrary Units
(AU)) had considerably higher values than healthy per-
sons (n=50; mean=30 AU; p=0.0001) and patients with
inflammatory diseases (n=40; mean= 296 AU; p=0.096).
Within the group of patients with tumors, those 
in advanced stages (UICC 4) showed significantly
higher values than those in early stages (UICC 1–3)
(p=0.0004).
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Abbreviations: ABTS, 2,2’-azino-di-3-ethylbenzthiazo-
line-sulfonate, AU, Arbitrary Units; CV, coefficient of
variation; CDDE, Cell Death Detection- ELISAplus; E.coli,
Escherichia coli; EDTA, ethylenediamine tetraacetic
acid; ELISA, enzyme-linked immunosorbent assay;
mU, absorbance units x 10–3; S.aureus, staphylococcus
aureus; P.aeruginosa, Pseudomonas aeruginosa.
Introduction
Nucleosomes are basic elements of chromatin. They
are formed by a core particle which consists of an oc-
tamer of the histone components H2A, H2B, H3 and H4
and 146 base pairs of DNA which are wrapped around
them. Fifteen to 100 base pairs of linker-DNA connect
neighbouring nucleosomes and form a chain-like
structure which is stabilized by a further histone H1
(1–3). During cell death, particularly during apoptosis,
endonucleases are activated which bind specifically to
the easily accessible linking sites and cleave the chro-
matin into multiples of oligo- and mononucleosomes.
These are detectable in the cytoplasm at the early
stages of the apoptotic cell death process (4–8). The
degradation of the chromatin which occurs during on-
cotic cell death is less specific, but can also produce nu-
cleosome-like fragments (4, 5, 9). 
Nucleosomes which are released into circulation un-
der physiologic conditions are quickly and effectively
removed by hepatic metabolization or immunologic
elimination and can only be detected in small amounts
in the circulating blood (10–13). However, in the blood
of patients with diseases which are associated with in-
creased rates of cell death, such as the patients with
malignant tumors, acute inflammation or autoimmune
diseases, nucleosomes appear in elevated concentra-
tions (14–22). This might reflect the high rate of sponta-
neous, as well as of therapy-induced, cell death (14–16,
19–22). Additionally, increased active release of nucle-
osomes by lymphocytes might contribute to the en-
hanced amount of circulating nucleosomes (23).
In former studies, free DNA was quantified in serum
and plasma (14–16, 24, 25). As it was reported that
most of the circulating DNA exists as oligo- and
mononucleosomes (26, 27), we developed an easy-to-
handle method for the direct quantification of the nu-
cleosomes in serum or plasma. We used the Cell Death
Detection-ELISAplus (CDDE) from Roche Diagnostics
which originally was created as a cellular test system.
As the applicability to liquid materials was insufficient,
we performed various modifications and adapted the
CDDE for use in serum samples. 
Because of the quick elimination of nucleosomes
from circulation in vivo (13) and the presence of endonu-
cleases in serum in vivo and in vitro (28), the stability of
circulating nucleosomes is limited. Other groups also
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 14:03
Holdenrieder et al.: Nucleosomes in serum 597
reported the low reliability of the determination of nu-
cleosomes (29). We identified the pre-analytical han-
dling of the blood samples as an essential factor which
can considerably influence the test results. Inadequate
blood drawing, sample transport, centrifugation, stabi-
lization and storage conditions can provoke additional
release of nucleosomes from blood cells, or promote
nucleosomal degradation by endonucleases. 
We identified possible interfering factors and devel-
oped a standardized schedule for the pre-analytical
handling of samples. Together with the improved prop-
erties of the test system itself, these pre-analytical con-
siderations seem to be prerequisites for the reliable de-
termination of circulating nucleosomes in serum.
Materials, Methods and Patients
We purchased the Cell Death Detection-ELISAplus (CDDE) from
Roche Diagnostics (Mannheim, Germany) (No. 1774 425). The
method and the materials used are described in detail at the
Roche website (http:\\biochem.roche.com).
The assay is based on a quantitative sandwich enzyme-im-
munoassay principle. Two monoclonal mouse antibodies di-
rected against DNA (ss- and ds-DNA) and histones (H1, H2A,
H2B, H3 and H4) catch specifically mono- and oligonucleo-
somes which originate from the nucleus of eukaryotic cells.
As mitochondrial, prokaryotic, viral DNA and RNA are not as-
sociated with histones and do not show nucleosomal arrange-
ment, they are not detected by the CDDE. 
Materials
The materials for the CDDE were prepared as indicated at the
Roche website (http:\\biochem.roche.com) and included the
following:
• PBS (Phosphate Buffered Saline): Ready to use solution
containing 8.0 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, x 2 H2O, 0.2
g KH2PO4.
• Incubation Buffer: Ready to use solution containing phos-
phate buffered saline with 1% BSA, 0.5% Tween 20 and 1
mM EDTA.
• Anti-Histone-Biotin: Tablet of lyophilized biotinylated anti-
histone-antibodies (monoclonal antibodies from mouse
clone H11–4) which was dissolved in 450 µl distilled water
(50 µg/ml).
• Anti-DNA-POD: Tablet of lyophilized anti-DNA-antibodies
(monoclonal antibodies from mouse clone M-CA-33) with
activated peroxidase which was dissolved in 450 µl distilled
water (5 units/ml).
• Immunoreagent: 1/20 volumes of anti-DNA-POD and 1/20
volumes of anti-histone-biotin were thoroughly mixed with
18/20 volumes of incubation buffer before use.
• Substrate Buffer: Ready to use solution.
• Substrate: 3 tablets of 2,2’-azino-di-3-ethylbenzthiazoline-
sulfonate (ABTS) which were dissolved in 15 ml of substrate
buffer immediately before use.
• Streptavidin-coated microtiter plate. 
Assay procedure
Twenty µl of the sample (serum, diluted 1:4 with incubation
buffer) were placed into the streptavidin-coated microtiter
plate. Subsequently, 80 µl of the immunoreagent (see above)
were added; the microtiter plate was covered with an adhe-
sive foil and incubated for 2 hours on a microtiter plate shaker
(500 g). During the incubation period, the anti-histone anti-
body reacted with the histone-component of the nucleo-
somes. Simultaneously, it fixed the immunocomplex to the
streptavidin-coated microtiter plate by its biotin-component.
Additionally, the peroxidase-labeled anti-DNA antibody
bound to the DNA component of the nucleosomes. After re-
moval of unbound antibodies by a washing step (3 x 300 µl in-
cubation buffer), the amount of nucleosomes was quantified
by the peroxidase retained in the immunocomplex: the fixed
complexes were incubated with 100 µl ABTS on a plate shaker
at 250 g. The substrate reacted with the peroxidase, resulting
in color development proportional to the amount of nucleo-
somes captured in the antibody sandwich. After 30 min of
color development, the absorbance was measured photomet-
rically at 405 nm against substrate solution as a blank (refer-
ence wavelength 492 nm).
Matrix
We used serum as matrix because of its good stability and the
planned automation of the test. Ten ml of blood were collected
by venipuncture in caolin-affected tubes (Kabe) which are
used in clinical routine for serum investigations. One to two
hours after venipuncture, the samples were centrifuged at
3000 g for 10 min. Subsequently, 1/10 volumes of 100 mM
EDTA (in TRIS buffer, pH adjusted to pH 8) were added to 9/10
volumes of serum and mixed thoroughly.
Two hundred µl of the treated sera were placed in 2 ml tubes
and stored at –20 °C. After thawing, the samples were mixed
by vortex for 3 s. Subsequently, they were diluted with incu-
bation buffer (1/4 volumes of serum and 3/4 volumes of incu-
bation buffer) and mixed once again by vortex for 3 s. After-
wards, 20 µl of the diluted samples were placed into the
microtiter plate. 
Patients
We investigated sera from 310 persons: 50 healthy individu-
als, 40 patients with acute inflammation and 220 patients with
solid tumors, among them 34 with lung cancer, 55 with col-
orectal cancer, 41 with other gastrointestinal cancers, 51 with
breast cancer and 39 with ovarian cancer. The concentration
of nucleosomes in serum was quantified before the patients
underwent the recommended therapy (in malignant tumors
mostly surgery) to estimate the spontaneous rate of cell
death; 206 of these 220 patients with solid tumors had com-
plete staging investigations and were included in the evalua-
tion according to tumor stages.
Results
First investigations revealed deficiencies of the original
version of the CDDE regarding the comparability be-
tween different microtiter plates which also were ob-
served by other groups (29). Probably, the discrepancy
was caused by 1) the lack of a standardized time of color
development or, alternatively, a stop reagent; 2) the use
of an enrichment factor for the interpretation of the re-
sults which based on a negative control with a high in-
terassay variation; and 3) the lack of a standard curve. 
Standardization of the color development
First, we fixed the time of color development at 30 min.
Thus, the theoretical intraassay error which was due to
different periods of ABTS incubation because of man-
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ual performance of the assay, was decreased to less
than 5%. 
Standard curve
To enable reliable quantification of nucleosomes, we
established a standard curve using a reference material
which contained high amounts of nucleosomes. Ten ml
of EDTA blood from three healthy persons were mixed
and incubated at 37 °C (5% CO2) for 24 hours. After cen-
trifugation, the nucleosome-rich supernatant was
lyophilyzed and stored at 4 °C. After resuspension and
1:24 dilution with incubation buffer, after 30 min of
ABTS incubation the material reached reliable values
of about 2500 mU which is in the upper measuring
range of the photometer. Further dilution (1:24, 1:32,
1:48, 1:64, 1:96 and incubation buffer only) resulted in a
linear curve running through the origin. Nucleosomes
were quantified in Arbitrary Units (AU): after 30 min of
ABTS incubation, 1000 AU corresponded to 2500 mU,
500 AU to 1250 mU, 200 AU to 500 mU, etc. Whereas
the absorbance values measured in mU increased dur-
ing the color development, the values in AU were sta-
ble because of their direct relationship to the standard
curve.
Similarly to the standard curve, the dilution of serum
with incubation buffer (1:2, 1:4, 1:8, 1:16, incubation
buffer only) resulted in a linear and proportional curve.
Because many of the native serum samples exceeded
the measurable range at an ABTS incubation time of 30
min, we diluted all samples 1:4 with incubation buffer
(see above; Figure 1). 
The lowest detection dose (LDD) was calculated at 38
mU=16 AU using the formula: mean value (n=20)+3 x
standard deviation of the blank.
Analytical specificity
We titrated native anti-histone antibodies to the normal
immunoreagent which contained biotinylated anti-his-
Fig. 1 Standard curve for the detection of nucleosomes in serum. The standard curve as well as 
the serum dilution curve are linear and proportional lines which pass through the origin. 
Fig. 2 Analytical specificity. Anti-histone antibodies are
added by titration to the standard immunoreagent containing
biotinylated anti-histone antibodies. The measured signal
which decreases in a concentration-dependent manner into
the range of healthy persons (<100 AU) reflects the exclusive
quantification of complexes which are formed from biotiny-
lated anti-histone antibodies, nucleosomes and peroxidase-
labeled DNA antibodies (see text).
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tone antibodies and found declining absorbance val-
ues with increasing concentrations of the titrated na-
tive anti-histone antibodies. This observation indicated
1) that there was competition between native and bio-
tinylated anti-histone antibodies, 2) the absence of
other interfering factors within the test system, and 3)
that only nucleosomes which are bound to peroxidase
labeled anti-DNA antibodies and biotinylated anti-his-
tone antibodies were detected (Figure 2). DNA, his-
tones, nucleosomes, anti-histone antibodies or anti-
DNA antibodies alone could not produce a detectable
signal.
Imprecision
In order to estimate the reliability of the measurements
within one run and between several runs, we investi-
gated the imprecision using three pools with high (455
AU), intermediate (235 AU) and low (24 AU) ab-
sorbance values. At high and intermediate levels, the
intraassay coefficient of variation (n=10) ranged be-
tween 3.0% and 4.1%, the interassay coefficient of vari-
ation (n=14) between 8.6% and 13.5%. In lower ranges
of absorbance values, the coefficients increased to
12.4% in the intraassay and to 46.0% in the interassay
comparison (Table 1).
Stability
Because of the limited stability of nucleosomes in
serum or plasma, the choice of the matrix and the pre-
analytical handling of the samples deserves particular
emphasis: in the first step, we compared the serum and
EDTA-plasma matrices of 10 persons (4 healthy per-
sons, 4 patients with malignant tumors and 2 patients
with acute infections) and investigated the influence of
storage conditions such as storage time, temperature
and addition of a stabilizer (10 mM EDTA to pH 8).
We found in most cases (n=9) higher absorbance val-
ues in serum than in plasma. Only in one patient with
sepsis, values in both serum and plasma reached high
levels.
These serum and plasma samples were separated
into two groups with and without treatment with 10 mM
EDTA (pH 8). All samples were stored for 3 weeks at 
25 °C, 4 °C, –20 °C, and –80 °C. The best stability was ob-
served for serum treated with 10 mM EDTA (pH 8) after
centrifugation and stored at –20 °C or –80 °C (Figure 3).
Further, we investigated the pre-analytical handling
in detail, looking for possible adverse factors which
would affect the serum samples 1) between venipunc-
ture and centrifugation, 2) between centrifugation and
EDTA addition, 3) between EDTA addition and freezing,
4) during long-term storage and 5) between thawing
and test performance.
1) After venipuncture, we stored the samples at
37 °C, 25 °C and 4 °C for 0, 2, 4 and 6 hours before cen-
trifugation, treated them with EDTA immediately after
centrifugation and subsequently stored them at –20 °C.
With increasing delay before centrifugation, the ab-
sorbance values increased considerably. This effect
was particularly strong at a storage temperature of
37 °C and less prominent at 25 °C and 4 °C. 
2) After centrifugation (1 hour after venipuncture),
the serum samples were stored at 37 °C, 25 °C and 4 °C
before 10 mM EDTA (pH 8) was added after 0, 2, 4, 6 
and 8 hours. Subsequently, they were frozen at –20 °C




Pool 1 x¯=327 AU x¯=455 AU
CV=3.0 CV=8.6
Pool 2 x¯=181 AU x¯=235 AU
CV=4.1 CV=13.5
Pool 3 x¯=47 AU x¯=24 AU
CV=12.4 CV=46.0
Fig. 3 Type for sample and sample storage conditions for
nucleosome detection. Comparison between measurements
in serum (S) and plasma (P), with (+) and without (–)10 mM
EDTA (pH 8). Samples were stored at various temperatures
(here shown for –20 °C and –80 °C).
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(S1-S3). With increasing delay before adding EDTA, the
absorbance values decreased in a time-dependent
manner. The storage temperature had no impact on
these values (Figure 4). 
3) After centrifugation (1 hour after venipuncture)
and subsequent treatment with 10 mM EDTA, we
stored the serum samples at 37 °C, 25 °C and 4 °C for 0,
2, 4 and 8 hours before freezing them at –20 °C (E1–E3).
Neither the storage period before freezing nor the tem-
perature influenced the measured values (Figure 4).
4) We investigated the long-term stability using three
serum pools with low (55 AU), intermediate (297 AU)
and high (481 AU) absorbance values after storage pe-
riods of 1, 2, 3, 4 and 6 months at –20 °C. The values re-
mained constant, which was indicated by coefficents of
variation between 4.2% and 9.2% (Figure 5).
5) As 1:4 dilution of the serum with incubation buffer
was required, we investigated whether the dilution be-
fore and after freezing produced comparable absor-
bance values. At various levels, samples which were
diluted before freezing showed values about 50%
lower than samples which were diluted immediately
before measurement (Figure 6). Moreover, we per-
formed three freeze-thaw cycles with two serum sam-
ples and observed slightly increasing absorbance val-
ues. These results underlined the necessity to perform
the dilution of the samples only immediately before
measurement and to avoid the refreezing of the sam-
ples. 
After thawing, the serum samples were centrifuged
at 1600 g for 1 min or vortexed for 1, 3, 5, 10 and 20 s.
There were no differences in the resulting absorbance
values and the procedure was standardized to 3 s vor-
texing.
In vitro influences
We induced gentle hemolysis in a blood sample by
shaking and by exposition to 37 °C for 4 hours. After
centrifugation we spiked 250 µl serum with absorbance
Fig. 4 The effect of EDTA on nucleosome measurement.
Sera which were stored at 4 °C after centrifugation and to
which 10 mM EDTA (pH 8) was added (S1–3) after various pe-
riods, exhibit a decrease in the measured values depending
on the delay time. Sera to which 10 mM EDTA (pH 8) was
added immediately after centrifugation and which subse-
quently were stored for various periods at 4 °C (E1–3) show
stable values.
Fig. 5 Long-term stability of samples. Sera with low, medium
and high concentrations of nucleosomes exhibit a good stabil-
ity over at least 6 months after adding 10 mM EDTA (pH 8) and
storage at –20 °C.
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values below the lowest detection dose, with serum
from the hemolyzed blood in increasing amounts (1 µl,
2 µl, 3 µl, 5 µl, 10 µl). The values of the spiked serum in-
creased proportionally to the concentration of the
added hemolyzed serum. 
In a further experiment, we tested whether only DNA
of eukaryotic cells which is arranged in nucleosomes is
detected by CDDE or whether also prokaryotic DNA of
bacterial origin leads to measurable signals.
Several concentrations (102 cells/ml, 105 cells/ml, 108
cells/ml) of Escherichia coli (E.coli), Staphylococcus
aureus (S.aureus) and Pseudomonas aeruginosa
(P.aeruginosa) preserved in the Ringer solution were
incubated for 4 hours with antibiotics in increasing
doses (E.coli and S.aureus: Cefotaxim 1, 10 and 100
mg/ml; P.aeruginosa: Ceftazidim 1, 10 and 100 mg/ml).
Subsequently, the concentrations of nucleosomes
were determined in the supernatants. Even after killing
the highest concentration of bacteria with the highest
dose of antibiotics which should have resulted in high
amounts of DNA in the supernatant, we did not ob-
serve any detection signal in the CDDE. 
The same bacteria (102 cells/ml, 105 cells/ml, 108
cells/ml of each E.coli, S.aureus and P. aeruginosa)
were incubated in whole blood samples of a healthy
donor for 4 hours with the same concentrations of an-
tibiotics. Subsequently, the samples were centrifuged
and the nucleosomes were determined in the sera of
these samples. We observed very high values in the
CDDE for all concentrations of bacteria and all concen-
trations of antibiotics. These results suggest that bacte-
rial DNA itself cannot be detected by the CDDE, but,
when incubated in human blood, it can lead to a mas-
sive stimulation of cell death or to the active release of
Fig. 6 The effect of sample dilution before storage. Sera di-
luted with an incubation buffer mixture before storage (sam-
ple 1) show considerably lower measured values than sera
immediately diluted before measurement (sample 2).
Fig. 7 The effect of bacterial contamination on nucleosome
measurement. Various concentrations (here shown for 105
bacteria/ml) of E. coli (E.c.), S. aureus (S.a.) and P. aeruginosa
(P.a.) were incubated in the Ringer solution with various con-
centrations of antibiotics (E.c. and S.a.: 1, 10 and 100 mg/ml
Cefotaxim, P.a.: 1, 10 and 100 mg/ml Ceftazidim) for 4 hours re-
sulting in measured values at the lowest detectable dose (1).
Incubating the same bacteria and antibiotics in human blood,
the measured values reached high levels independently of the
concentration of the added antibiotics (2) (see text).
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nucleosomes (Figure 7).
Clinical applicability
The concentration of nucleosomes was very low in
serum of almost all healthy persons. It ranged from <16
AU to 150 AU with a median of 23 AU and a mean of 30
AU. In contrast, patients with solid tumors showed val-
ues ranging from low to very high (<16 AU to 1260 AU).
The median of all tumor patients was 210 AU and the
mean 361 AU. Among the various tumor entities, lung
cancer was associated with the highest levels of nucle-
osomes in serum (median 357 AU, mean 524 AU),
whereas the lowest levels were observed in colorectal
cancer (median 151 AU, mean 310 AU). Also in patients
with acute inflammatory disease, we found a broad
range of values (<16 AU to 1249 AU). The median
reached 134 AU and the mean 296 AU (Figure 8).
Whereas the discrimination between healthy persons
and patients with solid tumors as well as between
healthy persons and patients with inflammation was
statistically significant (p=0.0001 Wilcoxon test), it did
not reach the level of significance observed between
the patients with tumors and inflammatory disease
(p=0.096 Wilcoxon test). 
Within the group of patients with solid tumors, ad-
vanced stages (UICC 4) were associated with signifi-
cantly higher values than early stages (UICC 1–3;
p=0.0004 Wilcoxon test) (Figure 9). This phenomenon
was most evident in patients with gastrointestinal tu-
Fig. 8 Distribution of the spontaneous concentrations of nucleosomes in serum of healthy persons, 
patients with acute inflammatory disease and patients with various solid tumors.
Fig. 9 Distribution of the spontaneous concentrations of nucleosomes in serum of patients 
with various solid tumors according to the tumor stage.
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mors, whereas many patients with lung cancer and
breast cancer had already high values at early stages.
Discussion
The modifications of the Cell Death Detection-ELISAplus
(CDDE), including the standardization of the ABTS in-
cubation time at 30 min and the establishment of a
standard curve with AU, considerably enhanced the in-
traassay (CV<10%) and interassay (CV<15%) precision
of the CDDE and enabled a reliable and reproducible
quantitative determination of the concentration of nu-
cleosomes in liquid materials. 
Nucleosomes in serum mostly occur in the form of
mono- and oligonucleosomes in unknown proportions
(30). Depending on their arrangement in mono- or
oligonucleosomes (with or without tertiary structure),
they might have different accessibility to antibodies (5).
This means that the number of peroxidase-labeled
anti-DNA-antibodies does not necessarily reflect the
exact concentration of the nucleosomes. Therefore, we
determined the nucleosomes with a relative scale in
AU instead of absolute and possibly erroneous con-
centrations in ng/ml nucleosomes. 
Nucleosomes were detected in several matrices: in
serum, plasma, urine and cerebrospinal fluid (for urine
and cerebrospinal fluid: authors’ unpublished results).
In agreement with other studies on free DNA (16, 
24, 25), we found higher concentrations of nucleo-
somes in serum compared to plasma. This phenome-
non might be explained by the stress exerted on blood
cells during the clotting process before centrifugation
which causes additional apoptosis and enhanced re-
lease of DNA and nucleosomes (24). Moreover, plasma
samples contain chelators which inhibit the activity of
the Ca2+- and Mg2+-dependent endonucleases. Sub-
sequently, the cleavage of chromatin into oligo- and
mononucleosomes, and the disclosure of antibody
binding sites is impaired. Additionally, plasma proteins
might react with nucleosomes and mask their presence
in plasma. For our investigation, we used serum as a
matrix, considering its good stability after treatment
with 10 mM EDTA (pH 8).
The time-dependent increase in the nucleosome val-
ues which was due to the delay between venipuncture
and centrifugation could be explained by the induction
of apoptosis in vitro during clotting and the additional
release of nucleosomes. Furthermore, endonucleases
potentially start cleaving the tertiary structure of chro-
matin and uncover formerly hidden antibody binding
sites, which lead to a stronger detection signal by the
peroxidase-labeled anti-DNA-antibodies.
In contrast, the destruction of antibody binding sites
at the ends of the nucleosomes by endonucleases
which are still present in serum might be the reason for
the time-dependent decrease in the absorbance values
in case of delayed addition of EDTA after centrifugation
(28). EDTA in a concentration of 10 mM seems to inhibit
effectively the activity of the Ca2+- and Mg2+-dependent
endonuclease, DNase I. pH 8 neutralizes the acidifica-
tion which often accompanies cell death and creates
unfavorable conditions for DNase II, which is active at
pH 4.5 (31). If EDTA is added to serum immediately after
centrifugation, further fragmentation of nucleosomes
by endonucleases seems to be sufficiently suppressed. 
Exposition of the blood samples to heat or shaking
were other stress conditions for the blood cells and of-
ten produced hemolysis. Additional cell death in vitro
and release of nucleosomes count for the false-positive
values in these cases. 
High values were also obtained after incubation of
bacteria and antibiotics in full blood samples of healthy
persons. The signal could theoretically be caused by
prokaryotic DNA which was released from lysed bacte-
ria or by high amounts of nucleosomes from blood
cells which were attacked by bacteria or damaged by
antibiotics. As bacteria which were incubated in neutral
medium and lysed by antibiotics did not cause an in-
crease in the values, we could show that 1) prokaryotic
DNA does not interfere with the ELISA and 2) the signal
in the samples from healthy individuals incubated with
bacteria and antibiotics was probably due to in vitro
death of blood cells such as macrophages and poly-
morphonuclear neutrophils (32, 33).
In order to avoid those possibly interfering influ-
ences, we developed a standardized schedule for the
pre-analytical handling of blood samples as follows:
1. Careful venipuncture without producing hemoly-
sis.
2. Centrifugation within 1 to 2 hours after venipunc-
ture.
3. Addition of 10 mM EDTA immediately after cen-
trifugation.
4. Storage at –20 °C on the same day, and storage at
–80 °C for periods longer than 6 months.
5. Homogenization by vortex for 3 s after thawing.
6. Dilution with incubation buffer immediatly before
performing the test.
The possible clinical relevance of the CDDE was shown
by studying serum samples from persons with differ-
ent diseases. Whereas these first results show healthy
persons as a homogeneous group with very low val-
ues, patients with acute inflammation as well as those
with malignant diseases, show a broad range of val-
ues. The concentration of nucleosomes in serum might
reflect the rate of cell death (17, 34) and the acuteness
of the process. In patients with malignant tumors, it
probably corresponds with tumor type, activity and
mass, and is related to the variable degree of perfusion
and to the inter- and intratumoral heterogeneity of cells
to undergo cell death (14–16). However, high cellular
turnover at early stages can lead to high levels of nu-
cleosomes in some tumor types. In acute inflamma-
tion, the role of the acute-phase proteins has to be also
considered. They are able to bind to the anionic histone
component of the nucleosomes and delay their elimi-
nation from the circulation (35, 36). 
Other studies concerning the concentration of circu-
lating nucleic acids in plasma and serum, although
measured by different techniques, show comparable
results for various tumors (14–16). 
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Conclusion and Perspective
The modified version of the CDDE is a sensitive, reli-
able and reproducible method to quantify the concen-
tration of nucleosomes in serum. The standardized pre-
analytical handling of blood samples prevents the
effect of interfering factors. The spontaneous concen-
tration of nucleosomes might reflect the rate of cell
death particularly in active, well perfused tumors and
in acute inflammatory processes. Follow-up studies of
such patients on and off therapy might be useful for es-
timating the extent and activity of solid tumors, as well
as the sensitivity to therapy and the therapeutic effi-
cacy.
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